Cargando…

Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis

Detalles Bibliográficos
Autores principales:	John, Binu, Doshi, Akash, Deng, Yangyang, Mansour, Natalie, Barritt, A.Sidne, Moon, Andrew, Ioannou, George, Martin, Paul, Chao, Hann-Hsiang, Taddei, Tamar H, Kaplan, David, Dahman, Bassam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	POSTER PRESENTATIONS: Thursday 23 June: Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252350/ http://dx.doi.org/10.1016/S0168-8278(22)00818-2

Ejemplares similares

Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant
por: John, Binu, et al.
Publicado: (2022)

Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis
por: John, Binu V., et al.
Publicado: (2022)

Tu1258: EFFECTIVENESS OF COVID-19 VIRAL VECTOR JANSSEN AD.26.COV2.S VACCINE AND COMPARISON WITH MRNA VACCINES IN CIRRHOSIS
por: John, Binu V., et al.
Publicado: (2022)

782: COMPARISON OF INFECTION-INDUCED AND VACCINE-INDUCED IMMUNITY AGAINST CORONAVIRUS 2019 IN PATIENTS WITH CIRRHOSIS
por: John, Binu V., et al.
Publicado: (2022)

COVID-19 vaccination in liver cirrhosis: safety and immune and clinical responses
por: Canha, Maria Ines, et al.
Publicado: (2022)

Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis
por: Kaewdech, Apichat, et al.
Publicado: (2022)

Patients with decompensated cirrhosis and liver transplant recipients demonstrate poor humoral and cellular immune response against COVID-19 vaccine
por: Kulkarni, Anand, et al.
Publicado: (2022)

Presence of cirrhosis in chronic liver disease patients associates with a lower immune response to COVID-19 vaccines-a multicenter european study
por: Simão, André L., et al.
Publicado: (2022)

Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis
por: John, Binu V., et al.
Publicado: (2022)

Humoral and cellular immunity after vaccination against SARS-CoV-2 is reduced in patients with chronic liver disease
por: Samer, Al-Dury, et al.
Publicado: (2022)

Humoral, cellular, clinical responses and safety to SARS-CoV-2 messanger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study
por: Iavarone, Massimo, et al.
Publicado: (2022)

mRNA COVID-19 vaccine effectiveness in liver transplant patients
por: Khan, Muhammad, et al.
Publicado: (2022)

No effect of HBsAg positivity on antibody response after COVID-19 vaccine
por: Jargalsaikhan, Ganbolor, et al.
Publicado: (2022)

Knowledge, attitude and practice regarding COVID-19 vaccination among HCV infected patients in Georgia
por: Gulbiani, Lasha, et al.
Publicado: (2022)

Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy
por: D’Ambrosio, Roberta, et al.
Publicado: (2022)

Association between immunosuppressants and poor antibody responses to inactivated SARS-CoV-2 vaccines in patients with autoimmune liver diseases
por: Li, Hu, et al.
Publicado: (2022)

Combined COVID-19 vaccination and HIV and hepatitis C virus screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain
por: Valencia, Jorge, et al.
Publicado: (2022)

Evaluation of immune response and disease flares in metobolic-associated fatty liver disease patients following SARS-CoV-2 vaccination: a prospective cohort study
por: Shi, Junping, et al.
Publicado: (2022)

Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients
por: John, Binu V., et al.
Publicado: (2022)

Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
por: John, Binu V., et al.
Publicado: (2021)

Enhancing the cascade of hepatitis C care in community-recruited high-risk people who inject drugs during the COVID-19 pandemic: the Alexandros program
por: Sypsa, Vana, et al.
Publicado: (2022)

Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan
por: Ashraf Hussain, Md Razeen, et al.
Publicado: (2022)

A novel prognostic model including liver function parameters accurately predicts 30-day mortality in patients admitted with COVID-19
por: Lee, David Uihwan, et al.
Publicado: (2022)

Prognostic value of liver function test for COVID-19 hospitalized patients with respiratory disease
por: Mateu, Carlos Alventosa, et al.
Publicado: (2022)

The prognostic implications of liver function test abnormalities in patients admitted to hospital with COVID-19
por: Cohen, Jason, et al.
Publicado: (2022)

The impact of COVID-19 pandemic control measures on HCV treatment initiation in British Columbia, Canada
por: Janjua, Naveed, et al.
Publicado: (2022)

Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease
por: Younossi, Zobair, et al.
Publicado: (2022)

The impact of liver fibrosis on the immune response to SARS-CoV-2 vaccination in metabolic associated fatty liver disease patients
por: Freitas, Marta, et al.
Publicado: (2022)

COVID-19 vaccine induced autoimmune hepatitis-a first case series from India
por: Iyengar, Sowmya, et al.
Publicado: (2022)

Autoimmune hepatitis diagnosed after COVID-19 vaccination. Results from the spanish registry for autoimmune and cholestatic hepatitis
por: Barreira, Ana, et al.
Publicado: (2022)

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

COVID-19 in patients with cirrhosis: insights from the multinational LEOSS registry
por: Brozat, Jonathan Frederik, et al.
Publicado: (2022)

COVID-19 pandemic impact on alcoholic hepatitis healthcare utilisation
por: Nedumannil, Leya, et al.
Publicado: (2022)

Increased hospital admissions for alcohol-associated hepatitis during the COVID-19 pandemic in Alberta, Canada: a retrospective cohort study
por: Frolkis, Alexandra, et al.
Publicado: (2022)

Trends of alcohol-related liver disease hospitalisation during the COVID-19 pandemic
por: Ayonrinde, Oyekoya, et al.
Publicado: (2022)

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study
por: Jorgensen, Kristin, et al.
Publicado: (2022)

Acute hepatitis after COVID-19 vaccine: case series by the International autoimmune hepatitis group (IAIHG) and the european reference network on hepatological diseases (ERN RARE-LIVER)
por: Codoni, Greta, et al.
Publicado: (2022)

Pustulose exanthématique aiguë généralisée post-vaccin anti-COVID-19
por: Berrim, K., et al.
Publicado: (2023)

Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial.
por: Rosales Renteria, Luis Alejandro, et al.
Publicado: (2022)

Description des cas de COVID-19 post-vaccination dans un centre hospitalier universitaire (CHU)
por: Amour, S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o1o00966vs6l3935fp2ahjd8ea